Missouri Pharmacy Program – Preferred Drug List

Fibromyalgia Agents

Effective 06/02/2010
Revised 08/08/2019

Preferred Agents

- Duloxetine (20, 30, 60mg)
- Lyrica® Caps

Non-Preferred Agents

- Cymbalta®
- Duloxetine (40mg)
- Irenka™
- Lyrica® CR
- Lyrica® Soln
- Pregabalin Caps/Soln
- Savella®

Approval Criteria

- Appropriate diagnosis for each agent:

  Therapy will be approved for the following diagnostic criteria:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Approved Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibromyalgia</td>
<td>Duloxetine, Lyrica®, Savella®</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Duloxetine</td>
</tr>
<tr>
<td>Lumbago</td>
<td>Duloxetine</td>
</tr>
<tr>
<td>Peripheral neuropathy associated with diabetes</td>
<td>Lyrica®, Duloxetine</td>
</tr>
<tr>
<td>Postherpetic neuralgia</td>
<td>Lyrica®</td>
</tr>
<tr>
<td>Partial onset seizures</td>
<td>Lyrica®</td>
</tr>
<tr>
<td>Neuropathy post spinal cord injury</td>
<td>No available diagnosis code</td>
</tr>
<tr>
<td></td>
<td>Clinical Consultant Approval</td>
</tr>
</tbody>
</table>

- Failure to achieve desired therapeutic outcomes with a trial on 2 preferred agents
  - Documented trial period for preferred agents
  - Documented ADE/ADR to preferred agents
- Documented compliance on a current therapy regimen

Denial Criteria

- Failure to meet the approval criteria
- Concurrent use of Monoamine Oxidase Inhibitors
- Children 17 years of age and younger (Subject to Clinical Consultant Review)
• Lack of adequate trial on preferred agents
• After 90 days of Fibromyalgia Agent therapy, documentation of more than three medications from the five drug classes listed below:
  o In any combination as a treatment for fibromyalgia

Most Common Drug Classes Concurrently used in Fibromyalgia Treatment
  o Tricyclic Antidepressants (TCA)
  o Selective Serotonin Re-uptake Inhibitors (SSRI)
  o Serotonin-Norepinephrine Re-uptake Inhibitors (SNRI)
  o Antiepileptic’s
  o Skeletal Muscle Relaxants (e.g. Cyclobenzaprine)
  o Short-Acting Opioids*
  *Opioids are no longer recommended as first or second-line treatment due to addiction risks and adverse effects